From another board....

We still believe great things are in store for the company and that the remainder of the year will be prosperous for shareholders....One new study result does not a company make ... but maybe an additional one ... maybe an additional two ... maybe a licensing deal after that ... maybe another licensing deal after that ... (get the picture ;)

I don't know what I don't know, but I'm skeptical that "the remainder of the year will be prosperous for shareholders".  Additional preclinical studies and a deal or two (like Chiesi) will move us along the path but I doubt any of that will push us into prosperity (my definition: over a buck).  

IMO, what's most important for shareholders is to move 001 into clinical trials (unless Chiesi moves sooner). It's unfortunate that the timeline for a clinical trial was pushed out several times and then disappeared in the latest presentation.  I'm guessing they haven't found a partner to move it forward.  

BTW, I have no interest in being either positive or negative on BTI.  I just try to take a realistic view of where we are and where we are likely headed through the remainder of the year and beyond.